To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
3,682 Current news from the ressort products
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
Antisoma telomere targeting agent stops tumour growth in prostate cancer model
05-Nov-2004
London UK. Cancer drug developer Antisoma presents new data showing that one of its telomere targeting agents (TTAs) rapidly blocks prostate tumour growth in a human xenograft model. While in untreated control animals tumours grew to lethal size within 10 days, animals given the TTA experienced a ...
AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus
02-Nov-2004
AVI BioPharma, Inc. , and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) announced positive results from experiments testing the effect of AVI's NeuGene® antisense drugs against Ebola virus (EBOV) in vivo. The NeuGene compounds targeted several EBOV genes. These ...
Astex achieves drug discovery collaboration success with Schering AG
25-Oct-2004
Cambridge, UK. Astex Technology announced that it has completed a significant goal in its multi-target drug discovery collaboration with Schering AG. Financial terms were not disclosed. The collaboration was announced in May 2003 and is a four-year, multi-target based alliance for the discovery ...
First ever clinical trial based upon the isolation of a disease gene in a common disease
deCODE Announces Positive Results from Phase IIa Clinical Trial of DG031
20-Oct-2004
deCODE genetics announced the principal results from its Phase IIa information-rich clinical trial" of DG031, the company's developmental compound which is being studied for the prevention of heart attack. The trial was designed to examine the effect of various doses of DG031 on certain ...
The Good Virus - Reovirus' New Role as Cancer Fighter
20-Oct-2004
Viruses are undergoing an "extreme makeover" after a long-standing reputation as bothersome and in many cases, lethal to the human body. A virus named the Respiratory Enteric Orphan virus, or reovirus, has been discovered to have the ability to grow in and kill a broad range of cancer cells ...
Bayer Healthcare Selects Liquent's Insight Manager for Registrations to Improve Process Quality
18-Oct-2004
Brunthal, Germany. Liquent, Inc. today announced that Bayer Healthcare (BHC), an independent subgroup of Bayer AG, Leverkusen, has selected Liquent InSight(R) Manager for Registrations (IMR). InSight Manager for Registrations is part of the Liquent InSight product family - an integrated, ...
InNexus to Develop SuperAntibody for Treatment of Coronary Heart Disease (Plaque)
14-Oct-2004
InNexus Biotechnology, Inc. is pleased to announce that it has received approval from the TSX Venture Exchange for the acquisition of monoclonal antibodies and related intellectual property from ImmPheron Inc. of Lexington, Kentucky. InNexus intends to initiate the product development of the ...
Benitec Announces First ddRNAi Therapeutic License With Revivicor & the Allowance of its Canadian Patent
11-Oct-2004
Benitec is pleased to announce the granting of its first therapeutic license to Revivicor, Inc (Virginia, USA). Benitec's ddRNAi technology will be used in Revivicor's pioneering work in the field of regenerative medicine; being the replacement of human cells, tissues and organs. ddRNAi will be ...
Sigma-Aldrich and Rubicon Genomics announce GenomePlex(TM) Whole Genome Amplification Licensing Agreement
08-Oct-2004
St. Louis /Taufkirchen. Sigma-Aldrich, a leading Life Science and High Technology company, is pleased to announce a licensing agreement with Rubicon Genomics, a molecular diagnostics company known for development of the GenomePlex(TM) Whole Genome Amplification (WGA) technology, a highly ...
The World's Largest Insulin Plant Awarded for Engineering Excellence
06-Oct-2004
Copenhagen. The life science engineering company, NNE, was awarded the Haden Freeman Award for Engineering Excellence on 28 September 2004. The award was given to NNE for the fast track construction of the world's largest insulin plant, built for the healthcare company Novo Nordisk A/S. The Rt. ...
